Biotechnology

BriaCell Therapeutics

BriaCell Therapeutics released FY2026 Q1 earnings on December 11 (EST), actual revenue USD 0 (forecast USD 2.1 M), actual EPS USD -4.3513 (forecast USD -3.28)

BriaCell Therapeutics released FY2025 Q4 earnings on October 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.239 (forecast USD -12.11)

BriaCell Therapeutics released FY2025 Annual Earnings on October 15 (EST), actual revenue USD 0, actual EPS USD -62.1862 (forecast EPS USD -2.955)

Briacell Therapeutics Corp. Stock Trading Suspended by Regulator

BriaCell Therapeutics Corp. Plans to Issue 12 Million Units to Raise $15 Million

BriaCell Welcomes Mayo Clinic as New Clinical Site for Its Crucial Phase 3 Clinical Trials

BriaCell Announces Phase II Data for BRIA-IMT Outperforms Control

BriaCell Therapeutics Corp. Announces Significant Milestone in Bria-OTS Study

BriaCell Therapeutics Corp Updates Phase III Clinical Trial Sites

BriaCell Therapeutics Corp. Developing Novel Cancer Immunotherapy

BriaCell's Phase 3 Study for Metastatic Breast Cancer Receives Positive Recommendation

BriaCell Therapeutics Reports Increased Operational Losses

BriaCell Therapeutics released FY2025 Q3 earnings on June 16 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -16.4017 (forecast USD -17.6)

BriaCell Therapeutics released FY2025 9 Months Earnings on June 16 (EST), actual revenue USD 0, actual EPS USD -7.2707

Briacell Therapeutics Anticipates Quarterly Loss of $1.76 Per Share

BriaCell focuses on developing novel immunotherapies to change cancer treatment

BriaCell to Present Cancer Treatment Clinical Trial Results at ASCO Annual Meeting

DSMB Recommends Continued Use of Bria-IMT™ with Checkpoint Inhibitors

Bria-Imt Receives FDA Fast Track Designation for Phase 3 Study

BriaCell Announces Results of Phase 3 Clinical Trial for Metastatic Breast Cancer Bria-IMT

Vision Marine Tech

SRX Health Solutions

AMC Robotics

Cementos Pacasmayo Saa 

B Riley Financial

Venus Concept

Rezolve AI

Everbright Digital

Emerald

Aldeyra Therap

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap